Cargando…

A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study

BACKGROUND: Chronic obstructive pulmonary disease (COPD) causes 3 million deaths each year, yet 38% of COPD patients continue to smoke. Despite proof of effectiveness and universal guideline recommendations, smoking cessation interventions are underused in practice. We sought to develop an infograph...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Samir, Panchal, Puru, Sadatsafavi, Mohsen, Ghanouni, Parisa, Sin, Don, Pakhale, Smita, To, Teresa, Zafari, Zafar, Nimmon, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734321/
https://www.ncbi.nlm.nih.gov/pubmed/34991699
http://dx.doi.org/10.1186/s13722-021-00283-1
_version_ 1784627992415174656
author Gupta, Samir
Panchal, Puru
Sadatsafavi, Mohsen
Ghanouni, Parisa
Sin, Don
Pakhale, Smita
To, Teresa
Zafari, Zafar
Nimmon, Laura
author_facet Gupta, Samir
Panchal, Puru
Sadatsafavi, Mohsen
Ghanouni, Parisa
Sin, Don
Pakhale, Smita
To, Teresa
Zafari, Zafar
Nimmon, Laura
author_sort Gupta, Samir
collection PubMed
description BACKGROUND: Chronic obstructive pulmonary disease (COPD) causes 3 million deaths each year, yet 38% of COPD patients continue to smoke. Despite proof of effectiveness and universal guideline recommendations, smoking cessation interventions are underused in practice. We sought to develop an infographic featuring personalized biomedical risk assessment through future lung function decline prediction (with vs without ongoing smoking) to both prompt and enhance clinician delivery of smoking cessation advice and pharmacotherapy, and augment patient motivation to quit. METHODS: We recruited patients with COPD and pulmonologists from a quaternary care center in Toronto, Canada. Infographic prototype content and design was based on best evidence. After face validation, the prototype was optimized through rapid-cycle design. Each cycle consisted of: (1) infographic testing in a moderated focus group and a clinician interview (recorded/transcribed) (with questionnaire completion); (2) review of transcripts for emergent/critical findings; and (3) infographic modifications to address findings (until no new critical findings emerged). We performed iterative transcript analysis after each cycle and a summative qualitative transcript analysis with quantitative (descriptive) questionnaire analysis. RESULTS: Stopping criteria were met after 4 cycles, involving 20 patients (58% male) and 4 pulmonologists (50% male). The following qualitative themes emerged: Tool content (infographic content preferences); Tool Design (infographic design preferences); Advantages of Infographic Messaging (benefits of an infographic over other approaches); Impact of Tool on Determinants of Smoking Cessation Advice Delivery (impact on barriers and enablers to delivery of smoking cessation advice in practice); and Barriers and Enablers to Quitting (impact on barriers and enablers to quitting). Patient Likert scale ratings of infographic content and format/usability were highly positive, with improvements in scores for 20/21 questions through the design process. Providers scored the infographic at 77.8% (“superior”) on the Suitability Assessment of Materials questionnaire. CONCLUSIONS: We developed a user preference-based personalized biomedical risk assessment infographic to drive smoking cessation in patients with COPD. Our findings suggest that this tool could impact behavioural determinants of provider smoking-cessation advice delivery, while increasing patient quit motivation. Impacts of the tool on provider care, patient motivation to quit, and smoking cessation success should now be evaluated in real-world settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13722-021-00283-1.
format Online
Article
Text
id pubmed-8734321
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87343212022-01-07 A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study Gupta, Samir Panchal, Puru Sadatsafavi, Mohsen Ghanouni, Parisa Sin, Don Pakhale, Smita To, Teresa Zafari, Zafar Nimmon, Laura Addict Sci Clin Pract Research BACKGROUND: Chronic obstructive pulmonary disease (COPD) causes 3 million deaths each year, yet 38% of COPD patients continue to smoke. Despite proof of effectiveness and universal guideline recommendations, smoking cessation interventions are underused in practice. We sought to develop an infographic featuring personalized biomedical risk assessment through future lung function decline prediction (with vs without ongoing smoking) to both prompt and enhance clinician delivery of smoking cessation advice and pharmacotherapy, and augment patient motivation to quit. METHODS: We recruited patients with COPD and pulmonologists from a quaternary care center in Toronto, Canada. Infographic prototype content and design was based on best evidence. After face validation, the prototype was optimized through rapid-cycle design. Each cycle consisted of: (1) infographic testing in a moderated focus group and a clinician interview (recorded/transcribed) (with questionnaire completion); (2) review of transcripts for emergent/critical findings; and (3) infographic modifications to address findings (until no new critical findings emerged). We performed iterative transcript analysis after each cycle and a summative qualitative transcript analysis with quantitative (descriptive) questionnaire analysis. RESULTS: Stopping criteria were met after 4 cycles, involving 20 patients (58% male) and 4 pulmonologists (50% male). The following qualitative themes emerged: Tool content (infographic content preferences); Tool Design (infographic design preferences); Advantages of Infographic Messaging (benefits of an infographic over other approaches); Impact of Tool on Determinants of Smoking Cessation Advice Delivery (impact on barriers and enablers to delivery of smoking cessation advice in practice); and Barriers and Enablers to Quitting (impact on barriers and enablers to quitting). Patient Likert scale ratings of infographic content and format/usability were highly positive, with improvements in scores for 20/21 questions through the design process. Providers scored the infographic at 77.8% (“superior”) on the Suitability Assessment of Materials questionnaire. CONCLUSIONS: We developed a user preference-based personalized biomedical risk assessment infographic to drive smoking cessation in patients with COPD. Our findings suggest that this tool could impact behavioural determinants of provider smoking-cessation advice delivery, while increasing patient quit motivation. Impacts of the tool on provider care, patient motivation to quit, and smoking cessation success should now be evaluated in real-world settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13722-021-00283-1. BioMed Central 2022-01-06 2022 /pmc/articles/PMC8734321/ /pubmed/34991699 http://dx.doi.org/10.1186/s13722-021-00283-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Gupta, Samir
Panchal, Puru
Sadatsafavi, Mohsen
Ghanouni, Parisa
Sin, Don
Pakhale, Smita
To, Teresa
Zafari, Zafar
Nimmon, Laura
A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study
title A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study
title_full A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study
title_fullStr A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study
title_full_unstemmed A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study
title_short A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study
title_sort personalized biomedical risk assessment infographic for people who smoke with copd: a qualitative study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734321/
https://www.ncbi.nlm.nih.gov/pubmed/34991699
http://dx.doi.org/10.1186/s13722-021-00283-1
work_keys_str_mv AT guptasamir apersonalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT panchalpuru apersonalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT sadatsafavimohsen apersonalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT ghanouniparisa apersonalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT sindon apersonalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT pakhalesmita apersonalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT toteresa apersonalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT zafarizafar apersonalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT nimmonlaura apersonalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT apersonalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT guptasamir personalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT panchalpuru personalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT sadatsafavimohsen personalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT ghanouniparisa personalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT sindon personalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT pakhalesmita personalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT toteresa personalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT zafarizafar personalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT nimmonlaura personalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy
AT personalizedbiomedicalriskassessmentinfographicforpeoplewhosmokewithcopdaqualitativestudy